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The primary structure of p97 (mclanotransfcrrin) has been compared with other members of the transf’errin superfamily. A molecular structure 
of p97 has been modellcd based on the crystal structure of diferric rabbit serum transfcrrin. The most significant amino acid substitutions in p97 
are almost exclusively limited to only two regions; the C-lobe iron-binding cleft and the intcrlok contact region. The latter includes witbin the 
N-terminal obe a &-binding consensus equence found in metallopeptidases, and in the C-terminal lobe a glutamic acid residue (Glu-394)capablr 
ofcompleting apo:ential thermolysin-like &-r-binding site. Thus, p97 may have a Zn-binding potential, unique amongst the transferrin superfamily. 
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1. INTRODUCTION 
~97 (melanotransferin) is a tumour-associated differ- 
entiation antigen expressed at high levels in most human 
melanomas but present in only trace amounts in normal 
adult tissues [l]. Whilst most melanomas express be- 
tween 50,000-500,000 molecules/cell the normal adult 
tissues with the most abundant p97 expression (smooth 
muscle) possess only about 8,OOO/cell. The molecule is 
a membrane-bound protein whose extracellular domain 
shares approximately 40% sequence identity with mem- 
bers of the transferrin superfamily, hence its pseudonym 
[2]. The transferrins are bi-lobal iron-binding glycopro- 
tcins capable of sequestering two ferric irons together 
with synergistic anions at specific sites within each lobe. 
~97 has similarly been shown to bind iron [3]. 
sive antitumour immunotherapy. For example, recom- 
binant vaccinia virus expressing ~97 has been shown to 
induce an im:nune response in both mice and monkeys 
[6,7]. In an alternative approach, 3 anti-idiotypic anti- 
bodies against 96.5 (an antibody specific for p97” epi- 
tope) were demonstrated to completely inhibit the bind- 
ing of p97 to 96.5, however, they were unable to protect 
mice against p97-positive mouse melanoma cells [8]. 
In the absence of a crystal structure for p97 little is 
known of its 3D structure and, in partisular, how it 
differs from the soluble members of the transferrin su- 
perfamily for which there are two X-ray crystal struc- 
tures known; rabbit serum transferrin [9] and human 
lactoferrin [lo]. This has been the stimulus for this in- 
vestigation. 
The exact ro!e of ~97 is unclear, but it .mmay represent 
a descendent from an ancestral protein which existed 
prior to the emergence of the soluble transferrins 
(ovotransferrin, serum transferrin and lactoferrin) [4]. 
It has recently been suggested that an iron cell-surface 
binding component may be p97, implying its participa- 
tion in a transmembrane iron transport system alterna- 
tive to that of the transferrin receptor-mediated system 
[51. 
2. MATERIALS AND METHODS 
Interest in p97 has arisen as 2 consequence of its 
potential application in varicus fcrms of active and pas- 
With the exception of Manduca lransferrin [I I], whose preciss iron- 
binding characteristics have yet to be dctcrmincd, all transfcrrins for 
which complete amino acid sequences have been reported in the liter- 
ature were aligned in the following manner. Sequences were divided 
into individual N- and C-terminal lobes based on the position of the 
8/9 cxon junction observed in chicken ovotmnsfcrrin and human 
serum tmnsferrin [12-141, and which rcprcsents hedivision ofthe two 
halves of the duplicated lransfcrrin gene. For those sequences for 
which such information was not available the division was based on 
an initial alignment of the ~omplcte sequences. 
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Lobe sequences were aligned using the progrim suite AMPS [IS] 
based on a pseudo-phylogcnctic tree gcnemted by the method of Feng 
and Doolitde [16]. This alignment was subject o slight manual adjust- 
ment in order that it was consistent with an alignment ofhuman serum 
transferrin [17.18] and hums:1 lactofcrrin [10,19], based on the super- 
position of the crystal structures ofrabbit serum lransferrin [9,70] and 
human lactoferrin [IO]. rcspcclivcly. 
Using the above alignment all positions were identified which have 
identical or conservatively substituted residuea within a given lobe of 
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PB7-N GMEVRWCATSDPEQHKCGNMSEAFREAG IQPSLLCVRGTSADHCVQLIAAQEADAITL;GGAIYEA 
HST-N VPDKTVRWCAVSEHEATKCqSFRDHMKSV~PSDCPSPACVKKASYLDCIRAIAANEADAVTLDAGLVYDA 
PST-N VAQKTVRWCTISNQEANKCSSFRENMSKAV KNGPLYSCVKXSSYLDCIKAIRDKEADAVTLDAGLVFEA 
HLF-N GRRRSVQWCAVSNPEATKCFQWQRNMRKVR GPPVSCLKRDSPIQCIQAIAENRADAVTLDGGFIYEA 
MLF-N KATTVRWCAVSNSEEEKCLRWqNEMRKVG GPPLSCVKKSSTRQCI~~IVTNRADAMTLDGGTMFDA 
COT-N APPKSVIRWCTTSSPEEKKCNNLRDLTQQ EFlISLTCVqKATYLDCIKAIANNEADAISLDGGQVFEA 
____________________---~~-~----~~~---~-~-----------~~~---~~~~~~~~~~~~~~~~~~~~~~~~ 
HST-CIPEAPTDECKPVKWCALSHHPRLKCDEWSVNSV GKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIA 
PST-CIPDSSKNECKKVRWCAIGHEETQKCDAWSINSG GKIECVSAENTEDCIAKIVKGGADAMSLDGGYIYIA 
HLF-CIEEEVAARRARVVWCAVGEQELRKCNQWSGLSE GSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTA 
MLF-CIQQDVIASKARVTWCAVGSEEKRKCDQUNRDSR GRVTCTSFPTTEDCIVATMKGDADAMSLDGGY~YTA 
COT-CIQLTPSPRENRIQWCAVGKDEKSKCDRWSYYSN GDVECTVVDETKDCIIKIMKGEADAVALDGGLVYTA 
P97-Cl DPNRLPPYLRWCVLSTPEIQKCGDMAVAFRRQR LKPEIQCVSAKSPQHCMERIQAEQVDAVTLSGEDIYTA 
I 
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8/9 exon junction 
70 90 110 
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PBf-N GKE HGLKPVVGEVYDQEV GTSYYAYAYVRR SSMV TTDTLKGVKSCHTGlNRTVGWNY 
HST-N YLAP!!#LKPVVAEFYGSKE DPQTFYYAVAVVKKDS GFQMNQLRGKKSCHTGLGRSAG~NI 
PST-N GLAPYNLKPVVAEFYGQKD NPQTHYYAVAVVKKGS NFQWNiJLQGKRSCHTGLGRSADWIf 
HLF-N GLAPYKLRPVAAEVYGTER QPRTHYYAVAVVKKGC SFQLNELQGLKSCHTGLRRTAGWNV 
MLF-N GKPPYKLRPVAAEVYGTKE QPRTKYYAVAVVKNSS NFHLNQLQGLRSCHTGIGRSAGWKI 
COT-N GLAPYKLKPTAAEIYEHTE GSTTSYYAVAVVKKGT EFTVNDLQGKTSCHTGLGRSAGWNI 
____________________~--~~~~---~~~~~~~~~~~---~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
HST-C GK CGLVPVLAENYNKSD NCED TPEAGYFAVAYVKKSAS DLTWDNLKGKKSCHTAVGRTAGWNI 
PST-C OK CGLVPVLAENYKTEGE NCVN TPEKGYLAVAVVKKSSGPDLNWNNLKGKKSCHTAYDRTAGWNI 
HLF-C GK CGLVPVLAENYKSQQSSDPDPNCVD RPVEGYLAVAYVRRSDT SLTldNSVKGKKSCHTAVDRTAGWNI 
MLF-C GK CGLVPVLAENQKSSKSNGLD CVN RPVEGYLAVAAYRREDA GFTWCSLRGKKSCHTAVDRTAGWNI 
CQT-C GV CGLVPVMAERYDDES QCSKTDERP ASYFAVAVARKDS NVNk'NEiKGKKSCHTAVGRTAGWVI 
P97-C GKK YGLVPAAGEHYAPED SSNSYYVVAVYRRDSSHAFTLDBLRGKRSCHAGFGSPAGWDV 
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410 430 460 
130 150 170 190 
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P97-N PVGYLVESG RLSVMGCDVLKAVSDYFGGSCVPGAGETSYSESLCRLCRGDSS GECYCDKSPLLRYYDYSGA 
HST-N PIGLLYC DLPEPRKPLEKAVANFFSGSCAPCADGTDFPQ LCQLCPG CGCSTLNEYFGYSGA 
PST-N PMGLLYD QLPEPRKPIEKAVASFFSSSCVPCADPVNFPK LCQQCAGK GAEKCACSNHEPYFGYAGA 
HLF-N PIGTLRPFL NWTGPPEPTEAAVARFFSASCVPGADKGQFPN LCRLCAGT GENKCAFSSQEPYFSYSGA 
MLF-N PIGTLRPYL NWNGPPASLEEAVSKFFSKSCVPGAQKDRFPN LCSSCAGT GANKCASSPEBPYSGYAGA 
COT-N PIGTLLHWGAIEWEGIESGSVEQAVAKFFSASCVPGATIEQ KLCRQCKGD PKTKCA RNAPYSGYSGA 
L_^____~I_~_~__~~_~_~~~~~~~~-~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
HST-C PNGLLYNKI NHCRF DEFFSEGCAPGSKKD SS LCKLCMGS GLNLCEPNNKEGYYGYTGA 
PST-C PTGLLYNKI NSCKF DQFFGEGCAPGSQRN SS LCALCIGSERAPGRECLANNHERYYGYTGA 
HLF-C PMGLLFNQT GSCKF DEYFSQSCAPGSDPR SN LCALCfGDEq GENKCVPNSNERYYGYTGA 
MLF-C PMGLLANQT RSCKF NEFFSQSCAPGADPK SN LCALCXDEK GENKCAPNSKERYQGYTGA 
COT-C PMGLTHNRT GTCNF DEYFSEGCAPGSPPN SR LCQLCQCSGCIPPEKCVASSHEKYFGYTGA 
P97-C PVGALIQRG FIRPKDCDVLTAVSBFFNASCVPVNNPKNYPSSLCALCVCDEQ GRNKCVGNSQERYYGYRGA 
I I $ 1 I *$ 
470 490 610 630 
Fig. I. Alignment of the N- and C-terminal obes of transferrin sequences, ~97. HST, PST, HLF, MLF and COT r&r to ~37. human serum 
transferrin, pig strum ttansfcrrin, human lactaferrin, mouse lactaferrin and chicken ovotrunsfcrrin, respectively. Iron-binding residues are indicated 
by *, anion-binding residues by @, the proposed zinc-binding residues by #, and the most signiticant residue substitutions in ~97 by 5. The residues 
are numbered according to the sequence of ~97. Symbols at the ui:pcr and lower halves of each section refer to the N- and C-lobes, respectively. 
The zinc-binding consensus sequence (around residue 330) is shown boxed, as nro the C-terminal hclices of luctoferrin and human serum transferrin 
(based on that of rabbit :ransfcrrin) and the proposed mcmbrxe anchorofp37. 
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P97-N FRCLAEGAGDVAF"KHSTVLRNTDOKTtPSWO~ALLS~DFELLCRT)CSRADVTEHR~CHLARYPA~AVVVRA DT 
HST-N FKCLKDGAGDVAFVKHSTIFENLAN KADRDOYELLCLDNTRKDVDEYKDCHLARVPSHTVVARSHGG 
PST-N FNCLKEDAGDVAFYKHSTVLENLPD KADRDdYELLCRDNTRRPVDDYENCYLAtjVPSHAVVARSVDG 
HLF-N FKCLKDGAGDVAFIRRSTVFEDLSD EAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVAR5VNG 
MLF-N LRCLRDKAGDVAFTRGSTVFEBLPN KAERDlJYKLLCPDNT#KPVTEYKECHLAQVPSHAVVSR5TID 
COT-N FHCLKDGKGDVAFVKHTTVNENAPD LNDEYELLCLDGSRQPVDNYKTCNHARVAAHAVVARD DN 
--_----------__------------------------------------------------------------------ 
HST-C 
PST-C 
HLF-C 
MLF-C 
CDT-C 
P97-C 
FRCLYEK GDVAFVKHQTVPqNTQGKNPDPWAKNLNEKDYELLCLDCTVVTRK D 
FRCLVEK GDVAFVKDqVVQq~~TDGKNKnDWAKDLK9MaFELLCqNGAR~PVDNAENCHLARAPNHAVVARD D 
FRCLAENAGDVAFVKDVTVLqNTDGNNNEA#AKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVS~ D 
LRCLAEKAGNYAFLKDSTVL~NTDGKNTEEWARNLKD D 
LRCLVEK GDVAFIqnSTVEENTGCKNKADHAKNtqMPDFEtLCTDGRRA~~Vl~D~EC~~EVP~AVVVRP E 
FRCLVENAGDVAFVRHTTVFDNTNGHNSEPWAAELRSEDYELLCPNGARAEVSqFAACNLAqIPPHAVHVRP DT 
f s I$ I * I $ 
660 570 590 610 
I$ 8 I 
P97-N DGGLIFRLLNEGQRLFSHEGS 5FQMF5SEA 
HST-N KEDLIWELLNQAQEHFGKDK SKEFQLF5SPH 
PST-N qEDSIWELLNqACjEHFGRDK SPDFQLF5SSH G KDLLFKDSANGFLKIPSKMDSSLYLGY~YVTALRR 
HLF-N KEDAIWNLLRQAQEKFGKDK SPKFQLFG5PS GQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQN 
MLF-N KEEAIWELLRqSQEKFGKKQ ASGFQLFASPS GI)KDLLFKESAIGFVRVPQKVDVGLYLTFSYTTSIq# 
CUT-N KVEDIWSFLSKAQSDFGVDT KSDFHLFGPPGI~KDPVLKDLLFKDSAIMLKRYrSLHDS~LYLGFE~SAI~S 
HST-C KEACVHKILRQQQHLFGSNVTDCSGNFCLFRSET KDLLFRDDTVCLAKLHDRNTYEKYLGEFXVKAVGN 
PST-C KVTCVAEELLKQQAqFGRHVTDCSSSFCKFKSNT KDLLFFLDDTQCLARV GKTTYESYLGADYITAVAN 
HLF-C KVERLKqVLLHqQAKFGRNGSDCPDKFCLFQSET KNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITN 
MLF-C KVEVL!JQVVLDQQVQFGRNGqRCPGEFCLFQSKT KNLLFNDNTECLAXIPGKTTSEKYLGKEYVIATRR 
COT-C KANKIRDLLERQEKRFGVNGSE KSKFMMFESqN KDLLFKDLTKCLFKVRBGTTYKEFLGDKFYTVISN 
P97-C NIFTVYGLLDKAQDLFGDDHNK GFKMFDSSN YHG~DLLFKDATVRAVPVGEKTTYRGULGLDYVAALEG 
§i I I 8 $ I 
630 660 670 
8,+‘9 aon junction 
I 
I 
P97-N L LC I 
HST-N L REGTCl 
PST-N L REEISI 
HLF-N L RKS 1 
MLF-N L NKK l 
COT-N M RKD l 
__________"_____________cc______________- 
PST-C L RKCSTSKILLEACTFHSAKNPRVETTT 
HLF-C L KKCS PILLEACEFLRK 
MLF-C L KQCS%',~LEACAFLTQ' 
COT-C L KTCNPSDIILPMCSFLEGK 
P9?-C MSSqqCSGAA PAPGAPLLPLLLPALAARLLPPAq 
I I 
690 710 
16/l? exon junction 
5-l 
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the soluble transferrins, but which differ in ~97. In order 10 be more 
selective in highlighting the most significant of these substitutions 
these residues were subjecrcd to a filtering process which removed 
those which were: (i) ambiguous due to ambiguities in the alignment; 
(ii) those which were only conservative substitutions; and (iii) those 
for which at least one cxamplc of the substituted amino acid occurred 
in the other lobe. 
In order IO examine the positions of tbcse substituted residues in the 
tertiary structure of the molecule a model of p97 was built based 
primarily on the 3.3 A crystal structure of diferric rabbit serum trans- 
fcrrin (RST) [9.20]. Using the above determined alignment substitu- 
tions were made where necessary using TOM [2l] running on a 
CYBER 910-400 graphics workstation. Loops were modellod by se- 
lecting the most appropriate from the four lobes of known crystal 
structure (N- and C-lobes of RST and human lactoferrin) based pri- 
marily on a criterion of length, and secondarily on that of sequence 
similarity. Loops were excised from the appropriate structure after 
superposition of the elements of secondary structure immedialely prc- 
ceding and following the loop, using the graphics program WMATIF 
[23], and the geometry of the loop junctions was corrected using the 
REFI option witbin TOM. If no loop of identical length existed inser- 
tions or deletions were made, and adjusted manually and using REFI 
to give good stereochemistry. Despite the presence of seven pralines 
in this region the membrane-anchoring domain was modelled in a 
helical conformation (see below). The prolines were modellcd into an 
idealised helix by adjusling the main-chain torsion angles in accord 
with the average values observed in the sludy of Barlow and Thornton 
[23] for up to five residues either side of the proline. Since the number 
ofprolines result in many ovcrlappingsegmcnts which require contra- 
dictory torsion angles we were guided in these cases by the phi angles 
at i-l and i-3 which are observed to direr most from ideal values [23]. 
The helix was subsequently energy minim&d using the program 
WHATIF 1221. The residues identified as being the most significant 
substitutions in p97 were examined with respect o this modelled 3D 
structure. 
~97 has been shown by Jongcncel et al. [24] to possess the consensus 
sequence found in Zn-dependent metnllopeptidases such as thermoly- 
sin, and which forms the core of their active sites [24-261. The consen- 
sus sequence proposed by Jongeneel et al. [24] is **HEn*H& where 
* and (3, represent uncharged and hydrophobic residues, respectively, 
and where both histidincs form ligands to the zinc ion. In both thermo- 
lysin and the modelled structure of p97 this region adopts an alpha- 
helical conformation. In order to examine further the feasibility of the 
existence of a possible Zn-binding site in p97 the structures of the 
consensus regions of the two molecules were superposed using the 
program WHATtF [22]. The coordinate set used for the thcrmolysin 
structure was P3TLN, as deposited in the Brookhaven databank [26]. 
The resulting positions of the zinc ion and its remaining ligands (Glum 
166 and a water molecule) were examined for clashes and favourable 
interactions with the remainder of the p97 molecule. 
3. RESULTS AND DISCUSSION 
The alignment of sequences of six members of the 
transferrin superfamily is shown in Fig. 1. The iron- and 
anion-binding residues, as identified in Lhe crystal struc- 
tures of human lactoferrin, rabbit serum tronsferrin and 
a half-molecule fragment hereof [27], are indicated (* 
and @, respectively). Also shown arc residues identified 
as being the most significant residue changes in p97 in 
compariscn with the remaining (soluble transferrin) SE- 
quences, indicated by %. 
Fig. 2 shows the distribution of these residues in the 
modelled 30 structure. The figure shows C-a positions 
only, and clearly highlights that the majority of the 
58 
amino acid substitutions considered the most dramatic 
have occurred in one of the two localities; the C-termi- 
nal iron-binding cleft (including the iron- and anion- 
binding sites) and the interlobe contact region. Some of 
the changes at the C-lobe iron site have been previously 
noted [29], and this lobe, as expected, does not bind iron 
[28]. Specifically, the substitution, D-to-S402, affects 
one of the otherwise conserved iron-binding residues; 
R-to-S463 and T-to-A459 involve changes to the hydro- 
gen-bonding network which binds the carbonate anion; 
and T/S-to-P464 and G-to-E404 involve large changes 
to residues involved in stabilising the orientation of the 
aspartic acid ligand, as found in the crystal structure of 
rabbit serum transferrin half molecule [27]. 
The residue changes at the interlobe interface are 
partly due to the addition of a hydrophobic tail at the 
C-terminus of the ~97 sequence. This region has been 
predicted to form the membrane-anchoring domain [2], 
and is indicated on Fig. I, along with the region which 
forms the C-terminal helix in soluble transferrins, and 
the exon, 8/9, and 16117 splice junctions. It can be seen 
that the C-terminal helix of the soluble transferrins (an 
element of secondary structure unique to the C-terminal 
lobe) is encoded by exon 17, which is similarly unique 
to the C-terminal half cf the transferrin gene. The equiv- 
alent structure to this region in p97 is the membrane- 
anchoring helix. If it is the case that soluble transferrins 
were originally membrane proteins which only lost their 
membrane anchors after the gene duplication event (as 
has been suggested [4]) then the implication is that the 
Anal exon originally encoded a specific functional do- 
main [30], the membrane anchor, which became short- 
ened and folded between the N- and C-terminal obes. 
In the model shown (Fig. 2), the membrane anchor has 
been built such that it extends away from the protein 
surface. Only in such a way is its length sufficient to 
fully span a lipid bilayer. 
Although it cannot be asserted with confidence that 
this anchoring region is alpha-helical in nature it has 
been built as such despite the presence of seven prolines 
in this region because such short anchoring domains are 
generally believed to be helical in nature. This is in order 
to satisfy the hydrogen bonding functions of the back- 
bone amide and carbonyl groups within the lipid mem- 
brane. This can only otherwise be achieved through the 
formation of a beta-barrel structure, for which the p97 
anchor is not of sufficient length. There is no experi- 
mental evidence which sheds light on this matter, nor 
does the model suggest any alternative way in which the 
molecule may interact with the membrane. The result 
of the modelling is a helix which is substantially curved 
due to the radially asymmetric distribution of prolines 
about the helix axis but which avoids bad contacts. The 
conformation of this region does not affect the conclu- 
sions to be drawn in the present study and has only been 
included for the sake of completeness. The direction of 
this helix was chosen such that it has the same orisnta- 
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Fig. 2. Stereo C-alpha trace oT modcllcd ~97. The most significant residue substitutions in comparison with soluble transferrins are indicated by 
solid spheres. They can be seen to cluster in the C-lobe iron-binding cleft and at the interlobe interface. The N-terminal iron binding fita and 
proposed zinc site are indicated as is the hydrophobic C-terminal tail. 
tion with respect to the C-terminal lobe as does the 
interlobe helix to the N-terminal lobe of lactoferrin. 
Although this orientation cannot be asserted with abso- 
lute confidence it seems clear that in order to traverse 
the membrane the helix cannot adopt the same position 
as the C-terminal helix of soluble transferrins, ahypoth- 
esis supported by the absence of a disulphide bridge in 
this region which presumably allows the tail to adopt a 
different orientation [29], The concentration of substitu- 
tions at the lobe interface suggests that the relative ori- 
entations of the two lobes may be different in ~97. 
Anderson et al. [lo] have identified residues believed 
to be involved in the interaction between the two lobes 
of lactoferrin. These residues, which are responsible for 
the formation of two salt bridges and a hydrophobic 
patch, are shown in Table I together with their counter- 
parts in p97. Unlike the other soluble transferrins, in 
which at least one and normally both salt bridges iden- 
tified previously are at least theoretically possible, p97 
is the only sequence to possess neither. A similar argu- 
ment can be applied to those residues involved in hydro- 
phobic interactions where it can be seen that the nature 
of the C-terminal hydrophobic surface has been com- 
pletely altered by virtue of the presence of the mem- 
brane anchor and amino acid substitutions. These com- 
bined alterations have resulted in the loss of the normal 
lobe interface from p97 which, together with the ob- 
served concentration of the most significant residue 
changes in this region, suggests that it may either pos- 
sess a significantly different relative lobe orientation 
and/or possess a unique functic:i. 
Fig. 3 shows the consensus proposed by Jongeneel et 
al. [24] For Zn-metallopeptidoses together with the ther- 
molysin sequence and the region of ~97, which they 
observed to be compatible with the consensus. Also 
given are the assigned secondary structures for thermo- 
lysin and ~97, as given by the program of K.absch and 
Sander [3 11. As can be seen the consensus region adopts, 
or is predicted to adopt, a helical structure in both 
Table I 
Residues reported to he directly involved or possibly important in the 
interlobe interactions or Inaoferrin and their cmnlerparts in p!V 
Lactofcrrin P97 Commcnta 
N.lobe C-lobe N-lobe C-lobe 
Sufr bridges 
R313 with D379 4319 
D315 with K386 - 
Hydropfrob fcs 
v310 1316 
P311 A317 
1314 T320 
L3lS A323 
Y319 W324 
F32S L330 
A382 
L38S 
L682 
H3i36 
A393 
At least one and normally 
both present in other 
tranefertis 
The hydrophobiccharacter 
of these residues is 
largely conserved in 
other transferrin 
sequences 
E389 
4392 
No cqui- 
A683 valent due to 
F688 membrane 
L689 anchor 
59 
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Thcrmolysin A;; VGHELTHAV 148 
P97 LGHBYLHAM 333 
Thcrmolydn aaaaaaaaa 
P97 Caanaoaaa 
Fig. 3. The 2%metallopeptidase consensus sequence isshown together 
with that of thrrmolysin (a member of the metallopcptidase family) 
and the reSion of p97 between residues 325 and 333 which matches 
the consensus. * and @ refer to uncharged and hydrophobic residues, 
respectively. Given below the sequences i the secondary structure 
assignment for both proteins, where a and C desiSnetc helix and coil, 
respectively [31]. 
molecules. Based on this observation it was decided to 
test the hypothesis that p97 might contain a &-binding 
site. 
After least-squares superposition of the two mole- 
cules using the C-cr positions of the consensus equence 
no clashes were found between the Zn ion, its water 
ligand and the remainder of the p97 molecule. Furthcr- 
more, the superposition revealed that the closest equiv- 
alent C-a position to that of Glu-166 in thermolysin 
(which together with the two histidines of the consensus 
sequence completes the Zn coordination sphere) is also 
that of a glutnmic acid residue in p97 (Glu-394). This 
strongly suggests that a Zn-binding site might easily be 
formed by this constellation of residues in p97, and the 
presence of Glu-328 within the consensus equence indi- 
cates that it may also have peptidase activity. The equiv- 
alent residue in thermolysin (Glu-143) is believed to be 
the critic21 residue in catalysis [32,33]. More specifically 
the role of Glu-143 in thermolysin is probably to act as 
a general base and as a proton shuttle, transfering the 
abstracted proton from the Zn-bound water molecule 
and adding it to the scissile peptide nitrogen. Further- 
more, the fact that this residue is the most important 
component of the catalytic apparatus of Zn-metallopro- 
teinases is demonstrated by the observation that the 
only elements found in a truly equivalent spatial ar- 
rangement in thermolysin and the exopeptidase, car- 
boxypeptidase, are the zinc and Glu-143 [32,34]. The 
amino acid sequence and the remainder of the 3D struc- 
ture of carboxypeptidase are completely unrelated to 
those of thermolysin and yet they are believed to share 
a common catalytic mechanism. The modelled p97 Zn- 
binding site is shown together with that of thermo!ysin 
in Fig. 4. 
It is of note that the proposed Zn-site resides in the 
cleft between lobes (a common feature of catalytic sites) 
and that the Zn ion receives ligands from both lobes, as 
in thermolysin. As described above this particular re- 
gion of the p97 molecule shows many significant se- 
quence differences in comparison with other transfer- 
rins. Included amongst such substitutions are the pro- 
posed ligands, Glu-394 and His-331. His-327 is also 
unique to p97. This accumulated evidence, in conjunc- 
tion with the loss of iron-binding capacity in the C- 
terminal obe, suggests that p97 may have acquired an 
additional function, that of Zn-binding and, possibly, 
peptidase activity. Although, to our knowledge, no di- 
rect experimental evidence xists concerning Zn-binding 
or peptidase activity of p97, the evidence presented 
herein for the proposed site, although entirely theoreti- 
cally based, is compelling and merits further investiga- 
tion. 
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Fig. 4. The proposed &-binding site of p97 (bold lines) is shown together with that of thermolysin (thin lines) which was used for the modelling 
after superposition ofthe consensus sequences. The structure of the consensus region itself can be modelled without problem into p97. The remaining 
zinc &and (Glu-394) adopts a slightly different conformation to that observed in thermolysin but can still coordinate lo the Zn. The position of 
the water molecule is shown by the X, and the Zn by the sphere. 
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